Alkem Labs unit to buy up to 55% of Occlutech for $118 million

Alkem Laboratories' medical devices unit will buy up to a 55% stake in Switzerland's Occlutech Holding for 99.4 million euros ($118 million), the Indian pharma company said on Friday, marking ‌its entry into ⁠advanced ⁠cardiovascular devices.

The deal, expected to close by June ​2026 and subject to final agreements and regualtory approvals, will give ​Alkem MedTech access to high-value markets such as the United States, Japan, Germany and other Western European ​countries, Alkem MedTech Chief Executive ⁠Kaustav Banerjee ‌said in a statement.

The global medical devices market size is projected to grow to ⁠over $1 trillion by 2034 from $604.99 billion in 2026, according to market research and consulting services firm Fortune Business Insights.


Alkem is India's fifth-largest listed pharmaceutical company in terms of market share.

Occlutech, the second-largest player in Europe's minimally invasive cardiac implants segment, posted a revenue of 49.4 million ‌for 2025. It derives about 85% of its revenue from Europe and the U.S.

Alkem Laboratories ​also reported ⁠third-quarter consolidated net profit of 6.36 billion rupees, missing analyst estimates of 6.51 billion rupees, according to LSEG data.

Revenue ​rose nearly 11% to 37.37 billion rupees but fell short of estimates of 37.6 billion rupees.

Shares of the company settled 8% lower on the day.